JP2020189977A5 - - Google Patents

Download PDF

Info

Publication number
JP2020189977A5
JP2020189977A5 JP2020107176A JP2020107176A JP2020189977A5 JP 2020189977 A5 JP2020189977 A5 JP 2020189977A5 JP 2020107176 A JP2020107176 A JP 2020107176A JP 2020107176 A JP2020107176 A JP 2020107176A JP 2020189977 A5 JP2020189977 A5 JP 2020189977A5
Authority
JP
Japan
Prior art keywords
compound
compound according
oxo
therapeutic agent
terminated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020107176A
Other languages
English (en)
Japanese (ja)
Other versions
JP7066780B2 (ja
JP2020189977A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020189977A publication Critical patent/JP2020189977A/ja
Publication of JP2020189977A5 publication Critical patent/JP2020189977A5/ja
Priority to JP2022072939A priority Critical patent/JP2022109994A/ja
Application granted granted Critical
Publication of JP7066780B2 publication Critical patent/JP7066780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020107176A 2014-07-17 2020-06-22 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法 Active JP7066780B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022072939A JP2022109994A (ja) 2014-07-17 2022-04-27 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201462025991P 2014-07-17 2014-07-17
US62/025,991 2014-07-17
US201462027220P 2014-07-21 2014-07-21
US201462027193P 2014-07-21 2014-07-21
US62/027,193 2014-07-21
US62/027,220 2014-07-21
US201462027733P 2014-07-22 2014-07-22
US62/027,733 2014-07-22
US201562106194P 2015-01-21 2015-01-21
US62/106,194 2015-01-21
US201562187132P 2015-06-30 2015-06-30
US201562187064P 2015-06-30 2015-06-30
US62/187,064 2015-06-30
US62/187,132 2015-06-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2017523194A Division JP6722663B2 (ja) 2014-07-17 2015-07-17 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022072939A Division JP2022109994A (ja) 2014-07-17 2022-04-27 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Publications (3)

Publication Number Publication Date
JP2020189977A JP2020189977A (ja) 2020-11-26
JP2020189977A5 true JP2020189977A5 (https=) 2021-07-26
JP7066780B2 JP7066780B2 (ja) 2022-05-13

Family

ID=55079179

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2017523194A Active JP6722663B2 (ja) 2014-07-17 2015-07-17 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
JP2020107176A Active JP7066780B2 (ja) 2014-07-17 2020-06-22 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法
JP2022072939A Pending JP2022109994A (ja) 2014-07-17 2022-04-27 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2017523194A Active JP6722663B2 (ja) 2014-07-17 2015-07-17 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022072939A Pending JP2022109994A (ja) 2014-07-17 2022-04-27 マクロファージおよび他のマンノース結合ｃ型レクチン受容体高発現細胞を標的化するための化合物および組成物、ならびにそれらを使用して治療するおよび診断する方法

Country Status (5)

Country Link
US (1) US20220211680A1 (https=)
EP (1) EP3169792A4 (https=)
JP (3) JP6722663B2 (https=)
CA (1) CA2955438C (https=)
WO (1) WO2016011415A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
CA2955441C (en) * 2014-07-17 2023-03-14 Ohio State Innovation Foundation Dextran conjugates for targeting macrophages and other cd296-expressing cells
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
EP3522938A4 (en) * 2016-10-04 2020-06-24 Cardinal Health 414, LLC COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING MACROPHAGE-RELATED DISORDERS USING A CARBOHYDRATE MACROMOLECULAR SUPPORT
MX2019004033A (es) * 2016-10-07 2019-12-05 Navidea Biopharmaceuticals Inc Compuestos y composiciones para el tratamiento de la leishmaniasis y metodos de diagnostico y tratamiento que utilizan los mismos.
CN110139655A (zh) 2016-10-07 2019-08-16 纳维迪亚生物制药有限公司 诊断和治疗病毒性感染的化合物和方法
CA3070494A1 (en) * 2017-07-21 2019-01-24 Navidea Biopharmaceuticals, Inc. Use of 99mtc-tilmanocept and related molecular constructs for identifying and diagnosing malignant tumors and for monitoring therapeutic anti-tumor interventions
WO2020198622A1 (en) * 2019-03-27 2020-10-01 Navidea Biopharmaceuticals, Inc. Compositions and methods for altering macrophage phenotype
WO2021034953A1 (en) * 2019-08-19 2021-02-25 Navidea Biopharmaceuticals, Inc. Compositions and related methods for the ablation of m2 macrophages and myeloid derived suppressor cells
WO2021067479A1 (en) * 2019-09-30 2021-04-08 Navidea Biopharmaceuticals, Inc. Compositions and related methods for blocking off-target localization of mannosylated dextrans and other cd206 ligands
CA3168879A1 (en) 2020-07-08 2022-01-13 Navidea Biopharmaceuticals, Inc. Synthesis of uniformly defined molecular weight mannosylated dextrans and derivatives thereof
CA3192041A1 (en) * 2020-08-21 2022-02-24 Resolute Science, Inc. Compositions and methods for targeting tumor-associated macrophages
US11833170B2 (en) 2022-02-04 2023-12-05 Navidea Biopharmaceuticals, Inc. Altering net charge on mannosylated dextrans to maximize target tissue uptake and off target competitive blocking
EP4525882A1 (en) 2022-05-20 2025-03-26 Navidea Biopharmaceuticals, Inc. Cd206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
JP2025535006A (ja) 2022-10-03 2025-10-22 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 炭水化物ポリマーに結合されたアミン終端リーシュへの糖部分のアミド結合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228536T3 (es) * 1999-05-14 2005-04-16 The Regents Of The University Of California Soporte macromolecular a base de dextrano para un farmaco y suministro de un agente de diagnosotico.
WO2006093524A2 (en) * 2004-07-16 2006-09-08 The General Hospital Corporation Antigen-carbohydrate conjugates
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US20100196272A1 (en) * 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US9101674B2 (en) * 2010-03-29 2015-08-11 Vib Vzw Targeting and in vivo imaging of tumor-associated macrophages
WO2012171035A1 (en) * 2011-06-10 2012-12-13 University Of Washington Through Its Center For Commercialization Carbohydrate-based compositions and methods for targeted drug delivery
US20130330274A1 (en) * 2012-05-22 2013-12-12 University of Virginia Patent Foundation d/b/a University of Virginia Licensing & Ventures Group Compositions and methods for detecting and treating cancer
EP3024493A1 (en) * 2013-07-22 2016-06-01 Navidea Biopharmaceuticals, Inc. Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
CA2955441C (en) * 2014-07-17 2023-03-14 Ohio State Innovation Foundation Dextran conjugates for targeting macrophages and other cd296-expressing cells

Similar Documents

Publication Publication Date Title
JP2020189977A5 (https=)
JP3268913B2 (ja) 高分子担体
JP2020536845A5 (https=)
JP2020508985A5 (https=)
JP3270592B2 (ja) ブロック共重合体−抗癌剤複合体医薬製剤
JP5314590B2 (ja) カンプトテシン結合部分
JP2021073272A5 (https=)
JP5746615B2 (ja) 癌細胞への抗体の動員のためのキメラ小分子
JP2020536847A5 (https=)
JPH05117385A (ja) ブロツク共重合体の製造法、ブロツク共重合体及び水溶性高分子抗癌剤
EA002030B1 (ru) Полимерные производные камптотецинов
JP2021121590A5 (https=)
JP2010516675A (ja) 治療薬剤のポリマー担体および疾病部位の抗体に基づく標的化のための認識部分
JP2012025932A (ja) 分岐型ヘテロポリエチレングリコールおよび中間体
JPWO2019138367A5 (https=)
JP2011500725A5 (https=)
JP2003506319A (ja) ビタミンに関連したデュアルターゲッティング治療法
JP2020519676A5 (https=)
CA2497167A1 (en) Modified saccharides, conjugates thereof, and their manufacture
JPWO2020092907A5 (https=)
US20200297693A1 (en) Glucose conjugates of triptolide, analogs and uses thereof
JP2025176137A5 (https=)
JPWO2020173935A5 (https=)
JP2007505044A5 (https=)
JPWO2021055295A5 (https=)